Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Gujarat-Themis-Biosyn-Limited"

4 News Found

Gujarat Themis Biosyn acquires MicroBiopharm Japan for Rs. 1,300 Cr
News | May 23, 2026

Gujarat Themis Biosyn acquires MicroBiopharm Japan for Rs. 1,300 Cr

Transition to a fermentation-based globally integrated CDMO platform

Gujarat Themis Biosyn to acquire anti-TB and anti-infective brands from Sanofi for EUR 158 Million
News | April 24, 2026

Gujarat Themis Biosyn to acquire anti-TB and anti-infective brands from Sanofi for EUR 158 Million

Deal includes 13 branded generic products across 55+ countries; acquisition expected to strengthen global anti-infective portfolio and expand regulated market presence

Gujarat Themis Biosyn doubles fermentation production capacity at Vapi
News | October 19, 2025

Gujarat Themis Biosyn doubles fermentation production capacity at Vapi

With this expansion, the overall fermentation capacity of the company has increased from 450 KL to 990 KL

Amalgamation of Gujarat Themis Biosyn with Themis Medicare
News | November 23, 2024

Amalgamation of Gujarat Themis Biosyn with Themis Medicare

The Scheme is subject to approval of the secured creditors and shareholders of TML and GTBL

Upcoming E-conference
July 17, 2026 Biosimilars & Biologics: The Next Growth Frontiers for Indian Pharma

Latest Stories

Zealand Pharma’s petrelintide delivers double-digit weight loss in next-gen obesity treatment

Teva study shows Huntington’s disease treatment improves life for patients & caregivers

Oval & Merck Specialities sign strategic pact to expand access to advanced IVF care in India

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
Sanjay Vyas President and Managing Director, Parexel India And Global SBU Head- Safety services & Logistics, Parexel International
Cancer treatment must move beyond one-size-fits-all decisions: Dr. Manjiri Bakre, CEO and Founder, OncoStem Diagnostics
Cancer treatment must move beyond one-size-fits-all decisions: Dr. Manjiri Bakre, CEO and Founder, OncoStem Diagnostics
Dr. Manjiri Bakre CEO and Founder, OncoStem Diagnostics
We plan to invest nearly $100 million in new infrastructure, biologics and AI-driven drug discovery,: Akhil Ravi, CEO, Aurigene
We plan to invest nearly $100 million in new infrastructure, biologics and AI-driven drug discovery,: Akhil Ravi, CEO, Aurigene
Akhil Ravi Chief Executive Officer, Aurigene Pharmaceutical Services Limited

Packaging